Common gaming camera could be effective in evaluating walking difficulties of MS patients

NewsGuard 100/100 Score

A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients.

The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.

A team of researchers led by McGill University postdoctoral fellow Farnood Gholami, supervised by Jozsef Kövecses from the Department of Mechanical Engineering and Centre for Intelligent Machines, collaborated with Daria Trojan, a physiatrist in the Department of Neurology and Neurosurgery working at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals.

In current clinical practice, the walking movement of MS patients is usually assessed by their doctors, and subjective evaluations may distort results: two different clinicians may give the same patient different evaluations. Using a camera that detects movement and computer algorithms that quantify the patients' walking patterns can reduce potential for human error.

Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group using the Kinect device. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method.

Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. The investigators found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining his/her level of gait abnormality.

Gholami says he became interested in using motion capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. The Kinect device gave him an inexpensive tool to use that appears to be still accurate enough to do the job.

"This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not," he says. "Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson's disease."

Trojan says the tool could be useful "to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials."

Gholami says the next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device that promises to improve accuracy.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New platform can deliver gene therapy precisely to specific areas of the brain